Skip to main content

Strategies for eliciting HIV-1 inhibitory antibodies.

Publication ,  Journal Article
Tomaras, GD; Haynes, BF
Published in: Curr Opin HIV AIDS
September 2010

PURPOSE OF REVIEW: Major roadblocks persist in the development of vaccines that elicit potent neutralizing antibodies targeting diverse HIV-1 strains, similar to known broadly neutralizing HIV-1 human monoclonal antibodies. Alternatively, other types of anti-HIV-1 envelope antibodies that may not neutralize HIV-1 in traditional neutralization assays but have other anti-HIV-1 activities (hereafter termed HIV-1 inhibitory antibodies) can be elicited by current vaccine strategies, and numerous studies are exploring their roles in preventing HIV-1 acquisition. We review examples of strategies for eliciting potentially protective HIV-1 inhibitory antibodies. RECENT FINDINGS: Heterologous prime-boost strategies can yield anti-HIV immune responses, although only one (canarypox prime, Env protein boost) has been tested and shown positive results in an efficacy trial (RV144). Although the immune correlates of protection are as yet undefined, the reduced rate of acquisition without a significant effect on initial viral loads or CD4 T-cell counts, have raised the hypothesis of an RV144 vaccine-elicited transient protective B-cell response. SUMMARY: In light of the RV144 trial, there is a critical need to define the entire functional spectrum of anti-HIV-1 antibodies, how easily each can be elicited, and how effective different types of antibody effector mechanisms can be in prevention of HIV-1 transmission.

Duke Scholars

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

September 2010

Volume

5

Issue

5

Start / End Page

421 / 427

Location

United States

Related Subject Headings

  • Virology
  • Vaccination
  • Immunization, Secondary
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Clinical Trials as Topic
  • Antibodies, Neutralizing
  • AIDS Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tomaras, G. D., & Haynes, B. F. (2010). Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS, 5(5), 421–427. https://doi.org/10.1097/COH.0b013e32833d2d45
Tomaras, Georgia D., and Barton F. Haynes. “Strategies for eliciting HIV-1 inhibitory antibodies.Curr Opin HIV AIDS 5, no. 5 (September 2010): 421–27. https://doi.org/10.1097/COH.0b013e32833d2d45.
Tomaras GD, Haynes BF. Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS. 2010 Sep;5(5):421–7.
Tomaras, Georgia D., and Barton F. Haynes. “Strategies for eliciting HIV-1 inhibitory antibodies.Curr Opin HIV AIDS, vol. 5, no. 5, Sept. 2010, pp. 421–27. Pubmed, doi:10.1097/COH.0b013e32833d2d45.
Tomaras GD, Haynes BF. Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS. 2010 Sep;5(5):421–427.

Published In

Curr Opin HIV AIDS

DOI

EISSN

1746-6318

Publication Date

September 2010

Volume

5

Issue

5

Start / End Page

421 / 427

Location

United States

Related Subject Headings

  • Virology
  • Vaccination
  • Immunization, Secondary
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Antibodies
  • Clinical Trials as Topic
  • Antibodies, Neutralizing
  • AIDS Vaccines